World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
28965
World Ranking
13603
National Ranking
6911

Overview

Maria R. Baer is affiliated with the University of Maryland, Baltimore in the United States. Their research predominantly focuses on the field of Medicine, with significant contributions in Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health, and Oncology.

Their work addresses several main topics including Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, and Histone Deacetylase Inhibitors Research.

Maria R. Baer has published extensively, with frequent contributions to well-known journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Advances, and Cancer Research.

Several recent papers authored or co-authored by Maria R. Baer include:

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study, 2021, The Lancet
  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results, 2021, Blood
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial, 2020, Nature Medicine
  • Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial, 2022, The Lancet Haematology
  • Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis, 2021, Journal of Clinical Oncology

Frequent co-authors collaborating with Maria R. Baer include:

  • Gary J. Schiller
  • Vu H. Duong
  • Eunice S. Wang
  • William Blum
  • Uma Borate

Best Publications

  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

    Alexander E. Perl;Giovanni Martinelli;Jorge E. Cortes;Andreas Neubauer

  • IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

    Maria R. Baer;Stephen L. George;Richard K. Dodge;Kieran L. O'Loughlin

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    Bijal D Shah;Armin Ghobadi;Olalekan O Oluwole;Aaron C Logan

  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Alexander E. Perl;Jessica K. Altman;Jorge Cortes;Catherine Smith

  • Signal transducer and activator of transcription proteins in leukemias.

    Mustafa Benekli;Maria R Baer;Heinz Baumann;Meir Wetzler

  • Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

    Karthika Natarajan;Yi Xie;Maria R. Baer;Maria R. Baer;Douglas D. Ross

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

    Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  • Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

    David P. Steensma;Maria R. Baer;James L. Slack;Rena Buckstein

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered

    John C. Byrd;Richard K. Dodge;Andrew Carroll;Maria R. Baer

  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

    Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

  • Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

    Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

  • RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

    Jason H. Mendler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

    Peter Paschka;Guido Marcucci;Amy S. Ruppert;Susan P. Whitman

  • Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

    Misbah Qadir;Kieran L. O'Loughlin;Stacy M. Fricke;Nicole A. Williamson

  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

    J C Byrd;R B Weiss;D C Arthur;D Lawrence

  • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

    Sherif S. Farag;Kellie J. Archer;Krzysztof Mrózek;Amy S. Ruppert

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Richard A. Larson
Richard A. Larson University of Chicago
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Bayard L. Powell
Bayard L. Powell Wake Forest University
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Richard Stone
Richard Stone Harvard University
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Susan P. Whitman
Susan P. Whitman The Ohio State University
Mark J. Levis
Mark J. Levis Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers but seeking alternatives to traditional medical school, there are several flexible study options and in-demand roles to consider. Direct entry MSN online programs are an effective pathway for individuals with non-nursing backgrounds who wish to become advanced practice nurses quickly, often without first earning a BSN.

If you prefer a faster route into the field, ADN programs (Associate Degree in Nursing) offer streamlined training and may have less competitive admissions requirements compared to BSN programs.

Non-clinical roles are also a vital part of the healthcare system. The best medical billing and coding schools online provide training with financial aid options, preparing you for essential administrative positions supporting patient care.

Lastly, some nursing schools that don't require TEAS test offer alternative entry paths, reducing standardized test barriers and making nursing education even more accessible. Each of these pathways opens new opportunities in the dynamic field of healthcare.

Best Scientists Citing Maria R. Baer

Trending Scientists

Recently Published Articles